The long-term impacts of COVID-19 on confirmed cases at least 12 months post-infection in Wellington, New Zealand: an observational, cross-sectional study. Kearns, N., Kivi, N., Dickinson, E., Mayo, E., Eathorne, A., Anderson, A., Beasley, R., Thornley, C., & Nesdale, A. The New Zealand Medical Journal, 136(1578):77–93, July, 2023. abstract bibtex AIM: To explore the prevalence of ongoing symptoms and laboratory abnormalities in confirmed cases of COVID-19 from the first wave within the Greater Wellington Region, after at least 12 months post infection. METHOD: COVID-19 cases were obtained from EpiSurv. Eligible participants electronically completed questionnaires (Overall Health Survey, Patient Health Questionnaire-9 [PHQ-9], Generalised Anxiety Disorder-7 [GAD-7], Pittsburgh Sleep Quality Index, EuroQol 5 Dimension 5 Level [EQ-5D-5L], Fatigue Severity Scale [FSS], WHO Symptom Questionnaire, Modified Medical Research Council Dyspnoea Scale [mMRC Dyspnoea Scale]). Blood samples were analysed for cardiac, endocrine, haematological, liver, antibody, and inflammatory markers. RESULTS: Forty-two of 88 eligible cases undertook the study. Participants were enrolled at a median 628.5 days from symptom onset. Fifty-two point four percent felt that their current overall health was worse than it was prior to contracting COVID-19. Ninety percent of participants reported at least two ongoing symptoms since their acute illness. Between 45-72% of participants reported each of anxiety, depression, dyspnoea, pain/discomfort, and sleep difficulties, assessed using the GAD-7, PHQ-9, mMRC Dyspnoea Scale, EQ-5D-5L and FSS questionnaires respectively. There were minimal laboratory abnormalities. CONCLUSION: There is a high prevalence of ongoing symptoms following the first wave of COVID-19 infection in Aotearoa New Zealand. At a median of 1.7 years post infection, there is a wide spectrum of symptoms and symptom severity, although as an observational, cross-sectional study a causal relationship between symptoms or their severity and COVID-19 infection cannot be firmly established.
@article{kearns_long-term_2023,
title = {The long-term impacts of {COVID}-19 on confirmed cases at least 12 months post-infection in {Wellington}, {New} {Zealand}: an observational, cross-sectional study},
volume = {136},
issn = {1175-8716},
shorttitle = {The long-term impacts of {COVID}-19 on confirmed cases at least 12 months post-infection in {Wellington}, {New} {Zealand}},
abstract = {AIM: To explore the prevalence of ongoing symptoms and laboratory abnormalities in confirmed cases of COVID-19 from the first wave within the Greater Wellington Region, after at least 12 months post infection.
METHOD: COVID-19 cases were obtained from EpiSurv. Eligible participants electronically completed questionnaires (Overall Health Survey, Patient Health Questionnaire-9 [PHQ-9], Generalised Anxiety Disorder-7 [GAD-7], Pittsburgh Sleep Quality Index, EuroQol 5 Dimension 5 Level [EQ-5D-5L], Fatigue Severity Scale [FSS], WHO Symptom Questionnaire, Modified Medical Research Council Dyspnoea Scale [mMRC Dyspnoea Scale]). Blood samples were analysed for cardiac, endocrine, haematological, liver, antibody, and inflammatory markers.
RESULTS: Forty-two of 88 eligible cases undertook the study. Participants were enrolled at a median 628.5 days from symptom onset. Fifty-two point four percent felt that their current overall health was worse than it was prior to contracting COVID-19. Ninety percent of participants reported at least two ongoing symptoms since their acute illness. Between 45-72\% of participants reported each of anxiety, depression, dyspnoea, pain/discomfort, and sleep difficulties, assessed using the GAD-7, PHQ-9, mMRC Dyspnoea Scale, EQ-5D-5L and FSS questionnaires respectively. There were minimal laboratory abnormalities.
CONCLUSION: There is a high prevalence of ongoing symptoms following the first wave of COVID-19 infection in Aotearoa New Zealand. At a median of 1.7 years post infection, there is a wide spectrum of symptoms and symptom severity, although as an observational, cross-sectional study a causal relationship between symptoms or their severity and COVID-19 infection cannot be firmly established.},
language = {eng},
number = {1578},
journal = {The New Zealand Medical Journal},
author = {Kearns, Nethmi and Kivi, Neakiry and Dickinson, Emily and Mayo, Emma and Eathorne, Allie and Anderson, Augustus and Beasley, Richard and Thornley, Craig and Nesdale, Annette},
month = jul,
year = {2023},
pmid = {37414078},
keywords = {COVID-19, Cross-Sectional Studies, Dyspnea, Humans, New Zealand, Quality of Life, Surveys and Questionnaires},
pages = {77--93},
}
Downloads: 0
{"_id":"NTHaBSK2WBWTPZTwm","bibbaseid":"kearns-kivi-dickinson-mayo-eathorne-anderson-beasley-thornley-etal-thelongtermimpactsofcovid19onconfirmedcasesatleast12monthspostinfectioninwellingtonnewzealandanobservationalcrosssectionalstudy-2023","author_short":["Kearns, N.","Kivi, N.","Dickinson, E.","Mayo, E.","Eathorne, A.","Anderson, A.","Beasley, R.","Thornley, C.","Nesdale, A."],"bibdata":{"bibtype":"article","type":"article","title":"The long-term impacts of COVID-19 on confirmed cases at least 12 months post-infection in Wellington, New Zealand: an observational, cross-sectional study","volume":"136","issn":"1175-8716","shorttitle":"The long-term impacts of COVID-19 on confirmed cases at least 12 months post-infection in Wellington, New Zealand","abstract":"AIM: To explore the prevalence of ongoing symptoms and laboratory abnormalities in confirmed cases of COVID-19 from the first wave within the Greater Wellington Region, after at least 12 months post infection. METHOD: COVID-19 cases were obtained from EpiSurv. Eligible participants electronically completed questionnaires (Overall Health Survey, Patient Health Questionnaire-9 [PHQ-9], Generalised Anxiety Disorder-7 [GAD-7], Pittsburgh Sleep Quality Index, EuroQol 5 Dimension 5 Level [EQ-5D-5L], Fatigue Severity Scale [FSS], WHO Symptom Questionnaire, Modified Medical Research Council Dyspnoea Scale [mMRC Dyspnoea Scale]). Blood samples were analysed for cardiac, endocrine, haematological, liver, antibody, and inflammatory markers. RESULTS: Forty-two of 88 eligible cases undertook the study. Participants were enrolled at a median 628.5 days from symptom onset. Fifty-two point four percent felt that their current overall health was worse than it was prior to contracting COVID-19. Ninety percent of participants reported at least two ongoing symptoms since their acute illness. Between 45-72% of participants reported each of anxiety, depression, dyspnoea, pain/discomfort, and sleep difficulties, assessed using the GAD-7, PHQ-9, mMRC Dyspnoea Scale, EQ-5D-5L and FSS questionnaires respectively. There were minimal laboratory abnormalities. CONCLUSION: There is a high prevalence of ongoing symptoms following the first wave of COVID-19 infection in Aotearoa New Zealand. At a median of 1.7 years post infection, there is a wide spectrum of symptoms and symptom severity, although as an observational, cross-sectional study a causal relationship between symptoms or their severity and COVID-19 infection cannot be firmly established.","language":"eng","number":"1578","journal":"The New Zealand Medical Journal","author":[{"propositions":[],"lastnames":["Kearns"],"firstnames":["Nethmi"],"suffixes":[]},{"propositions":[],"lastnames":["Kivi"],"firstnames":["Neakiry"],"suffixes":[]},{"propositions":[],"lastnames":["Dickinson"],"firstnames":["Emily"],"suffixes":[]},{"propositions":[],"lastnames":["Mayo"],"firstnames":["Emma"],"suffixes":[]},{"propositions":[],"lastnames":["Eathorne"],"firstnames":["Allie"],"suffixes":[]},{"propositions":[],"lastnames":["Anderson"],"firstnames":["Augustus"],"suffixes":[]},{"propositions":[],"lastnames":["Beasley"],"firstnames":["Richard"],"suffixes":[]},{"propositions":[],"lastnames":["Thornley"],"firstnames":["Craig"],"suffixes":[]},{"propositions":[],"lastnames":["Nesdale"],"firstnames":["Annette"],"suffixes":[]}],"month":"July","year":"2023","pmid":"37414078","keywords":"COVID-19, Cross-Sectional Studies, Dyspnea, Humans, New Zealand, Quality of Life, Surveys and Questionnaires","pages":"77–93","bibtex":"@article{kearns_long-term_2023,\n\ttitle = {The long-term impacts of {COVID}-19 on confirmed cases at least 12 months post-infection in {Wellington}, {New} {Zealand}: an observational, cross-sectional study},\n\tvolume = {136},\n\tissn = {1175-8716},\n\tshorttitle = {The long-term impacts of {COVID}-19 on confirmed cases at least 12 months post-infection in {Wellington}, {New} {Zealand}},\n\tabstract = {AIM: To explore the prevalence of ongoing symptoms and laboratory abnormalities in confirmed cases of COVID-19 from the first wave within the Greater Wellington Region, after at least 12 months post infection.\nMETHOD: COVID-19 cases were obtained from EpiSurv. Eligible participants electronically completed questionnaires (Overall Health Survey, Patient Health Questionnaire-9 [PHQ-9], Generalised Anxiety Disorder-7 [GAD-7], Pittsburgh Sleep Quality Index, EuroQol 5 Dimension 5 Level [EQ-5D-5L], Fatigue Severity Scale [FSS], WHO Symptom Questionnaire, Modified Medical Research Council Dyspnoea Scale [mMRC Dyspnoea Scale]). Blood samples were analysed for cardiac, endocrine, haematological, liver, antibody, and inflammatory markers.\nRESULTS: Forty-two of 88 eligible cases undertook the study. Participants were enrolled at a median 628.5 days from symptom onset. Fifty-two point four percent felt that their current overall health was worse than it was prior to contracting COVID-19. Ninety percent of participants reported at least two ongoing symptoms since their acute illness. Between 45-72\\% of participants reported each of anxiety, depression, dyspnoea, pain/discomfort, and sleep difficulties, assessed using the GAD-7, PHQ-9, mMRC Dyspnoea Scale, EQ-5D-5L and FSS questionnaires respectively. There were minimal laboratory abnormalities.\nCONCLUSION: There is a high prevalence of ongoing symptoms following the first wave of COVID-19 infection in Aotearoa New Zealand. At a median of 1.7 years post infection, there is a wide spectrum of symptoms and symptom severity, although as an observational, cross-sectional study a causal relationship between symptoms or their severity and COVID-19 infection cannot be firmly established.},\n\tlanguage = {eng},\n\tnumber = {1578},\n\tjournal = {The New Zealand Medical Journal},\n\tauthor = {Kearns, Nethmi and Kivi, Neakiry and Dickinson, Emily and Mayo, Emma and Eathorne, Allie and Anderson, Augustus and Beasley, Richard and Thornley, Craig and Nesdale, Annette},\n\tmonth = jul,\n\tyear = {2023},\n\tpmid = {37414078},\n\tkeywords = {COVID-19, Cross-Sectional Studies, Dyspnea, Humans, New Zealand, Quality of Life, Surveys and Questionnaires},\n\tpages = {77--93},\n}\n\n","author_short":["Kearns, N.","Kivi, N.","Dickinson, E.","Mayo, E.","Eathorne, A.","Anderson, A.","Beasley, R.","Thornley, C.","Nesdale, A."],"key":"kearns_long-term_2023","id":"kearns_long-term_2023","bibbaseid":"kearns-kivi-dickinson-mayo-eathorne-anderson-beasley-thornley-etal-thelongtermimpactsofcovid19onconfirmedcasesatleast12monthspostinfectioninwellingtonnewzealandanobservationalcrosssectionalstudy-2023","role":"author","urls":{},"keyword":["COVID-19","Cross-Sectional Studies","Dyspnea","Humans","New Zealand","Quality of Life","Surveys and Questionnaires"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://api.zotero.org/users/6607533/collections/5UJPHGXV/items?key=hSjrOPQRRHHWY81SKs6CEz45&format=bibtex&limit=100","dataSources":["dPx74HjPZJdjhJvfM","pwX9v8DsjLkZCDK4r"],"keywords":["covid-19","cross-sectional studies","dyspnea","humans","new zealand","quality of life","surveys and questionnaires"],"search_terms":["long","term","impacts","covid","confirmed","cases","months","post","infection","wellington","new","zealand","observational","cross","sectional","study","kearns","kivi","dickinson","mayo","eathorne","anderson","beasley","thornley","nesdale"],"title":"The long-term impacts of COVID-19 on confirmed cases at least 12 months post-infection in Wellington, New Zealand: an observational, cross-sectional study","year":2023}